Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Imaging, Three-Dimensional | 5 | 2016 | 94 | 1.590 |
Why?
|
| Mammaplasty | 4 | 2022 | 7 | 1.110 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2013 | 174 | 0.800 |
Why?
|
| Zebrafish | 4 | 2016 | 146 | 0.770 |
Why?
|
| Breast | 4 | 2022 | 139 | 0.760 |
Why?
|
| Toxicity Tests | 2 | 2013 | 44 | 0.720 |
Why?
|
| Algorithms | 4 | 2013 | 509 | 0.690 |
Why?
|
| Silicon | 1 | 2020 | 17 | 0.640 |
Why?
|
| Breast Neoplasms | 6 | 2023 | 1723 | 0.630 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2020 | 72 | 0.610 |
Why?
|
| Mass Screening | 1 | 2022 | 541 | 0.550 |
Why?
|
| Automation | 2 | 2013 | 22 | 0.480 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2013 | 58 | 0.460 |
Why?
|
| Cell Nucleus | 2 | 2014 | 383 | 0.450 |
Why?
|
| Embryo, Nonmammalian | 3 | 2016 | 59 | 0.440 |
Why?
|
| Environmental Pollutants | 2 | 2016 | 201 | 0.420 |
Why?
|
| Blood Vessels | 1 | 2011 | 36 | 0.330 |
Why?
|
| Mastectomy | 3 | 2021 | 21 | 0.330 |
Why?
|
| Biological Assay | 1 | 2011 | 63 | 0.330 |
Why?
|
| Computer Communication Networks | 1 | 2010 | 12 | 0.320 |
Why?
|
| Medical Informatics | 1 | 2010 | 25 | 0.310 |
Why?
|
| User-Computer Interface | 1 | 2010 | 74 | 0.310 |
Why?
|
| Arsenic | 1 | 2011 | 155 | 0.290 |
Why?
|
| Software | 1 | 2010 | 236 | 0.270 |
Why?
|
| Humans | 21 | 2023 | 43102 | 0.260 |
Why?
|
| Patient Satisfaction | 2 | 2017 | 165 | 0.240 |
Why?
|
| Telemedicine | 1 | 2010 | 234 | 0.240 |
Why?
|
| Autophagy | 2 | 2016 | 140 | 0.200 |
Why?
|
| Autoanalysis | 1 | 2002 | 2 | 0.190 |
Why?
|
| Image Cytometry | 1 | 2002 | 6 | 0.190 |
Why?
|
| Prenatal Diagnosis | 1 | 2002 | 11 | 0.190 |
Why?
|
| Glioblastoma | 2 | 2014 | 74 | 0.190 |
Why?
|
| Fetus | 1 | 2002 | 101 | 0.190 |
Why?
|
| RNA-Binding Proteins | 1 | 2023 | 161 | 0.180 |
Why?
|
| Transplantation, Autologous | 1 | 2021 | 8 | 0.180 |
Why?
|
| Models, Theoretical | 2 | 2013 | 232 | 0.160 |
Why?
|
| Boron Compounds | 1 | 2020 | 18 | 0.160 |
Why?
|
| Nanocomposites | 1 | 2020 | 22 | 0.160 |
Why?
|
| Adipose Tissue | 1 | 2021 | 182 | 0.150 |
Why?
|
| Titanium | 1 | 2020 | 48 | 0.150 |
Why?
|
| Cell Adhesion | 1 | 2020 | 238 | 0.150 |
Why?
|
| Fruit | 1 | 2020 | 178 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2022 | 502 | 0.130 |
Why?
|
| Personal Satisfaction | 1 | 2017 | 76 | 0.130 |
Why?
|
| Cosmetic Techniques | 1 | 2016 | 4 | 0.130 |
Why?
|
| Body Image | 1 | 2017 | 89 | 0.130 |
Why?
|
| Photogrammetry | 1 | 2016 | 1 | 0.130 |
Why?
|
| Normal Distribution | 1 | 2016 | 14 | 0.130 |
Why?
|
| Animals, Genetically Modified | 2 | 2016 | 100 | 0.130 |
Why?
|
| Cardiovascular System | 1 | 2016 | 37 | 0.120 |
Why?
|
| Quality of Life | 2 | 2022 | 616 | 0.120 |
Why?
|
| Androgens | 2 | 2016 | 106 | 0.120 |
Why?
|
| Lysosomes | 1 | 2016 | 86 | 0.120 |
Why?
|
| Anthropometry | 1 | 2016 | 97 | 0.120 |
Why?
|
| Embryonic Development | 1 | 2016 | 83 | 0.120 |
Why?
|
| Receptors, Androgen | 1 | 2016 | 144 | 0.120 |
Why?
|
| Prostatic Neoplasms | 2 | 2016 | 1092 | 0.110 |
Why?
|
| Female | 9 | 2023 | 24698 | 0.110 |
Why?
|
| Posture | 1 | 2015 | 61 | 0.110 |
Why?
|
| Sodium Compounds | 1 | 2014 | 11 | 0.110 |
Why?
|
| Diploidy | 1 | 2013 | 6 | 0.110 |
Why?
|
| Disease Progression | 1 | 2016 | 667 | 0.100 |
Why?
|
| Aneuploidy | 1 | 2013 | 24 | 0.100 |
Why?
|
| Middle Aged | 5 | 2017 | 12222 | 0.100 |
Why?
|
| Cell Line | 2 | 2016 | 1410 | 0.100 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 592 | 0.100 |
Why?
|
| Arsenites | 1 | 2014 | 54 | 0.100 |
Why?
|
| Neovascularization, Physiologic | 1 | 2014 | 80 | 0.100 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 87 | 0.100 |
Why?
|
| Adoptive Transfer | 1 | 2013 | 53 | 0.100 |
Why?
|
| Embryonic Stem Cells | 1 | 2013 | 55 | 0.100 |
Why?
|
| Endothelial Cells | 1 | 2016 | 329 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2013 | 69 | 0.100 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 90 | 0.100 |
Why?
|
| Adult | 5 | 2017 | 13872 | 0.090 |
Why?
|
| Models, Animal | 1 | 2013 | 151 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 140 | 0.090 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2014 | 300 | 0.090 |
Why?
|
| Water Pollutants, Chemical | 1 | 2014 | 171 | 0.090 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 1081 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2014 | 536 | 0.090 |
Why?
|
| Models, Anatomic | 1 | 2011 | 18 | 0.090 |
Why?
|
| Observer Variation | 1 | 2011 | 59 | 0.080 |
Why?
|
| Lipids | 1 | 2012 | 256 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 968 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 386 | 0.080 |
Why?
|
| Surface Properties | 1 | 2011 | 160 | 0.080 |
Why?
|
| Computer Security | 1 | 2010 | 6 | 0.080 |
Why?
|
| Equipment and Supplies | 1 | 2010 | 10 | 0.080 |
Why?
|
| Telemetry | 1 | 2010 | 14 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 1 | 2011 | 256 | 0.080 |
Why?
|
| Photography | 1 | 2010 | 50 | 0.080 |
Why?
|
| Animals | 5 | 2016 | 16992 | 0.080 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 532 | 0.080 |
Why?
|
| Aged | 3 | 2017 | 8214 | 0.080 |
Why?
|
| Point-of-Care Systems | 1 | 2010 | 35 | 0.080 |
Why?
|
| Endopeptidases | 1 | 2009 | 64 | 0.070 |
Why?
|
| Young Adult | 2 | 2016 | 5080 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2010 | 408 | 0.070 |
Why?
|
| Cell Cycle Proteins | 1 | 2009 | 241 | 0.060 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 2676 | 0.060 |
Why?
|
| Telomere | 1 | 2023 | 59 | 0.050 |
Why?
|
| Computers | 1 | 2002 | 35 | 0.050 |
Why?
|
| Cell Proliferation | 3 | 2016 | 1455 | 0.050 |
Why?
|
| Prognosis | 2 | 2016 | 861 | 0.050 |
Why?
|
| Microscopy | 1 | 2002 | 35 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2022 | 120 | 0.050 |
Why?
|
| Minority Health | 1 | 2022 | 95 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2002 | 411 | 0.040 |
Why?
|
| Research Personnel | 1 | 2022 | 206 | 0.040 |
Why?
|
| Models, Biological | 2 | 2015 | 712 | 0.040 |
Why?
|
| Egg White | 1 | 2020 | 1 | 0.040 |
Why?
|
| Egg Yolk | 1 | 2020 | 2 | 0.040 |
Why?
|
| Surface Tension | 1 | 2020 | 12 | 0.040 |
Why?
|
| Viscosity | 1 | 2020 | 46 | 0.040 |
Why?
|
| Cellulose | 1 | 2020 | 24 | 0.040 |
Why?
|
| Curcumin | 1 | 2020 | 118 | 0.040 |
Why?
|
| Neoplasms | 1 | 2009 | 1377 | 0.030 |
Why?
|
| Minority Groups | 1 | 2022 | 690 | 0.030 |
Why?
|
| Radiotherapy, Conformal | 1 | 2016 | 2 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2016 | 20 | 0.030 |
Why?
|
| Pregnancy | 1 | 2002 | 1772 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 2016 | 157 | 0.030 |
Why?
|
| Green Fluorescent Proteins | 1 | 2016 | 209 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 237 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 611 | 0.030 |
Why?
|
| Calibration | 1 | 2015 | 63 | 0.030 |
Why?
|
| Texas | 1 | 2016 | 457 | 0.030 |
Why?
|
| Equipment Design | 1 | 2015 | 145 | 0.030 |
Why?
|
| Body Height | 1 | 2015 | 53 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 170 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 231 | 0.030 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2013 | 2 | 0.030 |
Why?
|
| Recurrence | 1 | 2014 | 152 | 0.030 |
Why?
|
| Mice | 2 | 2016 | 6644 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2013 | 17 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2013 | 158 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1063 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 355 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 173 | 0.020 |
Why?
|
| Lipogenesis | 1 | 2012 | 19 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 704 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2014 | 346 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 296 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 508 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 1604 | 0.020 |
Why?
|
| Prevalence | 1 | 2016 | 1612 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 347 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 247 | 0.020 |
Why?
|
| United States | 1 | 2022 | 5205 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 148 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 925 | 0.020 |
Why?
|
| Umbilicus | 1 | 2010 | 4 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 436 | 0.020 |
Why?
|
| Nipples | 1 | 2010 | 20 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 945 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2009 | 80 | 0.020 |
Why?
|
| Chromosome Segregation | 1 | 2009 | 45 | 0.020 |
Why?
|
| Logistic Models | 1 | 2009 | 1009 | 0.010 |
Why?
|
| Male | 2 | 2016 | 23409 | 0.010 |
Why?
|